ARTV Artiva Biotherapeutics, Inc.

NASDAQ
$11.45

Artiva Biotherapeutics, Inc. (ARTV) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.6% since its last earnings release on August 6, 2026.

Artiva Biotherapeutics Beat Consensus Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · After Close
Earnings Whisper
-
vs ($0.54)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology